2022
DOI: 10.1016/j.adro.2022.101059
|View full text |Cite
|
Sign up to set email alerts
|

The Effect of Cochlear Dose on Hearing Preservation After Low-Dose Stereotactic Radiosurgery for Vestibular Schwannomas: A Systematic Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 52 publications
0
7
1
Order By: Relevance
“…In another study, which compared GammaKnife, LINAC-based, and CyberKnife radiosurgery in relatively smaller vestibular schwannomas, LINAC provided the best conformity and GammaKnife the best gradient index [40] . The reported Paddick’s conformity index is better in the current study than in several other studies: 0.78–––0.85 in the current study versus 0.66–––0.76 (all without utilizing treatment margins or set-up robustness) [37] , [40] .…”
Section: Discussioncontrasting
confidence: 65%
See 1 more Smart Citation
“…In another study, which compared GammaKnife, LINAC-based, and CyberKnife radiosurgery in relatively smaller vestibular schwannomas, LINAC provided the best conformity and GammaKnife the best gradient index [40] . The reported Paddick’s conformity index is better in the current study than in several other studies: 0.78–––0.85 in the current study versus 0.66–––0.76 (all without utilizing treatment margins or set-up robustness) [37] , [40] .…”
Section: Discussioncontrasting
confidence: 65%
“…There is a lack of normal tissue complication probability (NTCP) models for hearing loss based on cochlear dose in vestibular schwannoma patients undergoing radiosurgery [11] . Previous photon radiosurgery studies suggest that better hearing outcomes can be obtained by reducing the mean doses < 3–6 Gy, the maximum doses < 4–12 Gy, and minimum doses < 5–6 Gy [37] , [38] . No established gold standard for radiotherapy exists for vestibular schwannoma patients, and differences in local practices (i.e., patient selection) and endpoint definitions (Dmean, Dmin, Dmax, D90, V90, cochlear modiolus dose) make it difficult to compare different modalities [10] , [14] , [33] .…”
Section: Discussionmentioning
confidence: 99%
“…Although some authors have asserted a strong connection between SRS treatment parameters such as cochlear dose and hearing loss after SRS, this remains controversial and is not uniformly considered in treatment planning. Therefore, associations between cochlear dose and hearing loss in the repeat SRS setting were not examined (42,43).…”
Section: Discussionmentioning
confidence: 99%
“…A maximum point dose of 12.5 Gy for uninvolved brainstem was also given 13 . For the clinical plans, a cochlea mean dose of 6 Gy was used as the OAR constraint 14,15 . When cochlea abutted the GTV, planners planned for mean dose as low as reasonably achievable while not compromising TC.…”
Section: Methodsmentioning
confidence: 99%
“…13 For the clinical plans, a cochlea mean dose of 6 Gy was used as the OAR constraint. 14,15 When cochlea abutted the GTV, planners planned for mean dose as low as reasonably achievable while not compromising TC. MFP and FIP were performed as follows.…”
Section: Treatment Planningmentioning
confidence: 99%